Servier Affaires Medicales
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$29.8M
Doctors Paid
52
Transactions
288
2024 Total
$52,831
Payment Breakdown by Category
Research$29.5M (99.1%)
Consulting$205,271 (0.7%)
Travel$37,019 (0.1%)
Food & Beverage$1,643 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.5M | 219 | 99.1% |
| Consulting Fee | $205,271 | 34 | 0.7% |
| Travel and Lodging | $37,019 | 13 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,698 | 4 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $11,900 | 3 | 0.0% |
| Food and Beverage | $1,643 | 15 | 0.0% |
Payments by Type
Research
$29.5M
219 transactions
General
$269,530
69 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| DFCI ALL CONSORTIUM PROTOCOL 16-001: RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF PEGASPARGASE IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | $17.0M | 0 | 2 |
| DFCI ALL Consortium Protocol 16-001 Randomized comparison of fixed dosing vs. pharmacokinetically guided dose-adjusted administration of Pegaspargase in children and adolescents with newly diagnosed ALL | $4.3M | 0 | 10 |
| TREATMENT OF NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS | $3.3M | 0 | 4 |
| DFCI ALL Consortium Protocol 16-001 Randomized Comparison of Fixed Dosing vs. Pharmacokinetically Guided Dose-Adjusted Administration of Calaspargase Pegol in Children and Adolescents with newly diagnosed ALL | $1.7M | 0 | 4 |
| DFCI ALL CONSORTIUM PROTOCOL 16-001: RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF CALASPARGASE PEGOL IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | $970,147 | 0 | 2 |
| A phase III randomized trial of Blinatumomab for newly diagnosed bcr-abl-negative lineage acute lymphoblastic leukemia in adults | $930,787 | 0 | 3 |
| TOTXVII Total therapy study XVII for newly diagnosed patients with Acute Lymphoblastic Leukemia and Lymphoma | $528,734 | 0 | 2 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics | $139,172 | 0 | 3 |
| A novel Pediatric-Inspired Regimen with Reduced Myelosuppressive Drugs for Adults aged 18-60 with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | $125,210 | 0 | 1 |
| A041501-PP1 Evaluation of Asparaginase pharmacokinetics and its effect on toxicities and clinical outcomes in Adolescents and Young Adults with newly diagnosed precursor B-Cell ALL | $91,773 | 0 | 2 |
| Longitudinal retrospective Cholangiocarcinoma chart review study | $89,945 | 0 | 4 |
| Evaluation of Health Burden in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia Therapy | $87,988 | 0 | 3 |
| A PHASE III RANDOMIZED TRIAL OF BLINATUMOMAB FOR NEWLY DIAGNOSED BCR-ABL-NEGATIVE LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS | $74,406 | 0 | 1 |
| STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | $70,434 | 12 | 138 |
| CALGB 10403 An intergroup Phase II Clinical Trial for adolescents and young adults with untreated Acute Lymphoblastic Leukemia ALL. | $52,300 | 0 | 1 |
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) | $16,667 | 8 | 14 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | $11,555 | 7 | 14 |
| STUDY OF AG-120 (IVOSIDENIB) VS. PLACEBO IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA WITH AN IDH1 MUTATION (AGILE) | $5,743 | 2 | 4 |
| Real-world treatment patterns and patient characteristics among patients with acute myeloid leukemia (AML) in the USA, UK, and France | $2,114 | 1 | 2 |
| PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (SUNLIGHT) | $1,547 | 1 | 3 |
| Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH) | $1,268 | 1 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Neurology | $71,601 | 8 | $8,950 |
| Internal Medicine | $65,047 | 9 | $7,227 |
| Hematology & Oncology | $40,114 | 9 | $4,457 |
| Hematology | $37,300 | 1 | $37,300 |
| Psychiatry | $32,435 | 2 | $16,218 |
| Student in an Organized Health Care Education/Training Program | $28,756 | 2 | $14,378 |
| Endocrinology, Diabetes & Metabolism | $26,836 | 1 | $26,836 |
| Medical Oncology | $21,585 | 9 | $2,398 |
| Pediatric Hematology-Oncology | $17,829 | 3 | $5,943 |
| Specialist | $12,316 | 1 | $12,316 |
| Pediatrics | $9,876 | 1 | $9,876 |
| Vascular & Interventional Radiology | $6,702 | 3 | $2,234 |
| Neurological Surgery | $4,656 | 1 | $4,656 |
| Vascular Surgery | $3,806 | 2 | $1,903 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Dan Douer, M.d, M.D | Hematology | New York, NY | $37,300 | $0 |
| Dr. Domenico Accili, M.d, M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $26,836 | $0 |
| Timothy Cloughesy, Md, MD | Neurology | Los Angeles, CA | $24,429 | $0 |
| Dr. Joshua Zeidner, M.d, M.D | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $24,113 | $0 |
| Dr. Courtney Dinardo, Md, MD | Internal Medicine | Houston, TX | $22,787 | $0 |
| Dr. Vanita Aroda, Md, MD | Internal Medicine | Boston, MA | $18,500 | $0 |
| Dr. David Rubinow, Md, MD | Psychiatry | Chapel Hill, NC | $18,452 | $0 |
| Nancy Andreasen, Md, MD | Psychiatry | Iowa City, IA | $13,983 | $0 |
| Dr. David Kupfer, Md, MD | Specialist | Pittsburgh, PA | $12,316 | $0 |
| Dr. Vaibhav Sahai, M.d, M.D | Hematology & Oncology | Ann Arbor, MI | $11,701 | $0 |
| Dr. Ingo Mellinghoff, M.d, M.D | Internal Medicine | New York, NY | $11,498 | $0 |
| Patrick Wen, Md, MD | Neurology | Boston, MA | $10,696 | $0 |
| Lewis Silverman, Md, MD | Pediatrics | New York, NY | $9,876 | $0 |
| Dr. Scott Howard, Md, MD | Pediatric Hematology-Oncology | Memphis, TN | $9,379 | $0 |
| Dr. Katherine Peters, M.d. Ph.d, M.D. PH.D | Neurology | Durham, NC | $8,355 | $0 |
| Dr. Rachna Shroff, Md, MD | Hematology & Oncology | Tucson, AZ | $7,278 | $0 |
| Dr. Naval Daver, Mbbs, MBBS | Hematology & Oncology | Houston, TX | $7,140 | $0 |
| Joe Mendez, M.d, M.D | Neurology | Salt Lake City, UT | $7,096 | $0 |
| Dr. Jennifer Clarke, Md, Mph, MD, MPH | Neurology | San Francisco, CA | $7,095 | $0 |
| Dr. Stephen Hunger, Md, MD | Pediatric Hematology-Oncology | Phila, PA | $6,800 | $0 |
| Dr. Elizabeth Maher, Md, Phd, MD, PHD | Hematology & Oncology | Dallas, TX | $6,649 | $0 |
| Elizabeth Claus, Md Phd, MD PHD | Neurological Surgery | Boston, MA | $4,656 | $0 |
| Louis Nabors | Neurology | Birmingham, AL | $4,643 | $0 |
| Dr. Matthias Holdhoff, M.d, M.D | Medical Oncology | Baltimore, MD | $4,643 | $0 |
| Dr. Yoshie Umemura, M.d, M.D | Student in an Organized Health Care Education/Training Program | Phoenix, AZ | $4,643 | $0 |
About Servier Affaires Medicales
Servier Affaires Medicales has made $29.8M in payments to 52 healthcare providers, recorded across 288 transactions in the CMS Open Payments database. In 2024, the company paid $52,831. The top product by payment volume is ONCASPAR ($27.3M).
Payments were distributed across 14 medical specialties. The top specialty by payment amount is Neurology ($71,601 to 8 doctors).
Payment categories include: Food & Beverage ($1,643), Consulting ($205,271), Research ($29.5M), Travel & Lodging ($37,019).
Servier Affaires Medicales is associated with 1 products in the CMS Open Payments database.